Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Jordan D. Berlin

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7571-2385; OpenAlex author ID A5039492614, A5103689466. Sources: ClinicalTrials.gov.

Their work

Papers
42 (first author 6, last author 8)
Trials
2 (principal investigator on 2)
Grants
0
Labs led
2
Collaborators
168
Papers, trials and grants by year

2008: 1 trial · 2009: none · 2010: none · 2011: 2 papers · 2012: 1 paper · 2013: 2 papers · 2014: 3 papers · 2015: 2 papers, 1 trial · 2016: 6 papers · 2017: 2 papers · 2018: 5 papers · 2019: 3 papers · 2020: 4 papers · 2021: 1 paper · 2022: 2 papers · 2023: 2 papers · 2024: 3 papers · 2025: 2 papers · 2026: 2 papers

Papers 42

  1. Dynamics of the association between circulating levels of miRNA and pancreatic cancer risk through the years prior to pancreatic cancer diagnosis. Co-author DOI 10.1002/ijc.70452↗
  2. Setidegrasib in Advanced Non-Small-Cell Lung Cancer and Pancreatic Cancer. Co-author DOI 10.1056/nejmoa2600752↗
  3. Phase II study of elraglusib (9-ING-41), a GSK-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel in previously untreated metastatic pancreatic … Co-author DOI 10.1016/j.esmoop.2025.105122↗
  4. Choice of oncologist and influencing factors: analysis of the Pancreatic Cancer Action Network registry. Last author DOI 10.1093/oncolo/oyaf406↗
  5. Circulating microRNAs in association with pancreatic cancer risk within 5 years. Co-author DOI 10.1002/ijc.34956↗
  6. Palliative and supportive care underutilization for patients with locally advanced pancreatic cancer: review of the NCDB. Co-author DOI 10.1016/j.esmogo.2024.100049↗
  7. Executive Summary of the American Radium Society Appropriate Use Criteria for Neoadjuvant Therapy for Nonmetastatic Pancreatic Adenocarcinoma: Systematic Revie… Co-author DOI 10.1097/coc.0000000000001076↗
  8. Management of Patients With Pancreatic Cancer Using the "Right Track" Model. First author DOI 10.1093/oncolo/oyad080↗
  9. Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial. Co-author DOI 10.1200/jco.22.01134↗
  10. Consensus Statement on Mandatory Measurements for Pancreatic Cancer Trials for Patients With Resectable or Borderline Resectable Disease (COMM-PACT-RB): A Syst… Co-author DOI 10.1001/jamaoncol.2022.0168↗
  11. Trends in the Incidence and Treatment of Early-Onset Pancreatic Cancer. Co-author DOI 10.3390/cancers14020283↗
  12. Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: … Co-author DOI 10.1158/1078-0432.ccr-21-1789↗
  13. A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated … Co-author DOI 10.1007/s10637-019-00824-1↗
  14. Recent advances in the treatment of pancreatic cancer. Last author DOI 10.12688/f1000research.21981.1↗
  15. A Phase II, Single-Arm, Open-Label, Bayesian Adaptive Efficacy and Safety Study of PBI-05204 in Patients with Stage IV Metastatic Pancreatic Adenocarcinoma. Last author DOI 10.1634/theoncologist.2020-0440↗
  16. Safety and Efficacy of Andecaliximab (GS-5745) Plus Gemcitabine and Nab-Paclitaxel in Patients with Advanced Pancreatic Adenocarcinoma: Results from a Phase I … Co-author DOI 10.1634/theoncologist.2020-0474↗
  17. Advanced pancreatic cancer clinical trials: The continued underrepresentation of older patients. Last author DOI 10.1016/j.jgo.2018.11.001↗
  18. Potentially Curable Pancreatic Adenocarcinoma: ASCO Clinical Practice Guideline Update. Co-author DOI 10.1200/jco.19.00946↗
  19. Perioperative Gemcitabine + Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial. Co-author DOI 10.1245/s10434-019-07685-1↗
  20. Dual Src and EGFR inhibition in combination with gemcitabine in advanced pancreatic cancer: phase I results : A phase I clinical trial. Co-author DOI 10.1007/s10637-017-0519-z↗
  21. Harnessing the Immune System in Pancreatic Cancer. First author DOI 10.1007/s11864-018-0566-5↗
  22. Current Concepts in the Treatment of Resectable Pancreatic Cancer. First author DOI 10.1007/s11912-018-0685-y↗
  23. Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. Co-author DOI 10.1016/s1470-2045(18)30098-6↗
  24. A Phase II Study of Ganetespib as Second-line or Third-line Therapy for Metastatic Pancreatic Cancer. Co-author DOI 10.1097/coc.0000000000000377↗
  25. Preclinical Rationale for the Phase III Trials in Metastatic Pancreatic Cancer: Is Wishful Thinking Clouding Successful Drug Development for Pancreatic Cancer? Last author DOI 10.1097/mpa.0000000000000753↗
  26. Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. Co-author DOI 10.1200/jco.2017.72.4948↗
  27. Evaluation of Pancreatic Cancer Clinical Trials and Benchmarks for Clinically Meaningful Future Trials: A Systematic Review. Last author DOI 10.1001/jamaoncol.2016.0585↗
  28. A phase 1b study of erlotinib in combination with gemcitabine and nab-paclitaxel in patients with previously untreated advanced pancreatic cancer: an Academic … Co-author DOI 10.1007/s00280-016-2981-2↗
  29. Phase I trial of vorinostat added to chemoradiation with capecitabine in pancreatic cancer. Co-author DOI 10.1016/j.radonc.2016.04.013↗
  30. Randomized Phase II Trial of Irinotecan/Docetaxel or Irinotecan/Docetaxel Plus Cetuximab for Metastatic Pancreatic Cancer: An Eastern Cooperative Oncology Grou… Co-author DOI 10.1097/coc.0000000000000068↗
  31. The Past, Present, and Future of Pancreatic Cancer Clinical Trials. First author DOI 10.1200/edbk_159117↗
  32. Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Co-author DOI 10.1200/jco.2016.67.5553↗
  33. A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreate… Co-author DOI 10.1093/annonc/mdv264↗
  34. A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreate… Co-author DOI 10.1093/annonc/mdv477↗
  35. Phase II trial of sorafenib and erlotinib in advanced pancreatic cancer. Co-author DOI 10.1002/cam4.208↗
  36. Timing versus duration of adjuvant therapy for pancreatic cancer: all the lessons we need in life are taught to us as children. First author DOI 10.1200/jco.2013.53.5617↗
  37. Treatment of metastatic pancreatic adenocarcinoma: a review. Last author PMID 24683721↗
  38. Changing the way we do business: recommendations to accelerate biomarker development in pancreatic cancer. Co-author DOI 10.1158/1078-0432.ccr-12-2745↗
  39. Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design. Co-author DOI 10.1245/s10434-013-2886-9↗
  40. A phase I study of cetuximab in combination with gemcitabine and radiation for locally advanced pancreatic cancer. Co-author PMID 23077684↗
  41. Pancreatic cancer treatment and research: an international expert panel discussion. First author DOI 10.1093/annonc/mdq545↗
  42. Treatment of early-stage pancreatic cancer. Last author PMID 21456390↗

Trials 2

  1. Efficacy and Safety Study of PBI-05204 in Patients With Stage IV Metastatic Pancreatic Adenocarcinoma Principal investigator NCT02329717↗
  2. Sorafenib and Erlotinib in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery Principal investigator NCT00837876↗

Closest collaborators

The 25 strongest of 168 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Dana Backlund Cardin · 14 shared papers, 2011–2025 · strength 1.74
  2. Fei Ye · 3 shared papers, 2024–2026 · strength 0.74
  3. Michael Brian LaPelusa · 3 shared papers, 2022–2025 · strength 0.66
  4. Lynn McCormick Matrisian · 4 shared papers, 2016–2025 · strength 0.65
  5. Rajiv Agarwal · 2 shared papers, 2024–2025 · strength 0.51
  6. Veronica Wendy Setiawan · 2 shared papers, 2024–2026 · strength 0.47
  7. Hui Cai · 2 shared papers, 2024–2026 · strength 0.47
  8. Rachael Z. Stolzenberg‐Solomon · 2 shared papers, 2024–2026 · strength 0.47
  9. Xiao‐Ou Shu · 2 shared papers, 2024–2026 · strength 0.47
  10. Qiuyin Cai · 2 shared papers, 2024–2026 · strength 0.47
  11. Chan Shen · 2 shared papers, 2022–2024 · strength 0.39
  12. Cathy Eng · 2 shared papers, 2022–2024 · strength 0.39
  13. Laura Williams Goff · 5 shared papers, 2014–2019 · strength 0.33
  14. Anirban Maitra · 4 shared papers, 2016–2019 · strength 0.32
  15. Marc T Roth · 2 shared papers, 2020 · strength 0.30
  16. Vincent J. Picozzi · 2 shared papers, 2020–2023 · strength 0.28
  17. Hedy Lee Kindler · 3 shared papers, 2013–2023 · strength 0.28
  18. Ramya Thota · 3 shared papers, 2014–2018 · strength 0.27
  19. Nipun B. Merchant · 5 shared papers, 2012–2019 · strength 0.27
  20. Emily W. Chan · 4 shared papers, 2012–2018 · strength 0.25
  21. Teresa Mercade Macarulla · 2 shared papers, 2018–2026 · strength 0.25
  22. Christopher Cann · 1 shared paper, 2024 · strength 0.24
  23. Matthew H. G. Katz · 4 shared papers, 2013–2019 · strength 0.24
  24. Efrat Dotan · 2 shared papers, 2019–2020 · strength 0.23
  25. Bert H. O’Neil · 4 shared papers, 2015–2020 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.